Liminatus Pharma Reports $2.53 Million Net Loss and Significant Asset Growth in Latest 10-Q

Liminatus Pharma, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $2.53 million for the six months ended June 30, 2026, compared to a loss of $214,239 for the same period in 2025. Total operating expenses increased to $2.48 million, up from $1.38 million in the prior year, primarily driven by a $1 million increase in research and development expenses related to the company's CD47 license agreement. General and administrative expenses also rose by 7% to $1.48 million, reflecting the costs associated with operating as a publicly traded entity following the completion of its business combination.

The company experienced a notable change in its financial position, with total assets increasing to $3.40 million as of June 30, 2026, compared to $512,795 at the end of 2025. This increase was largely due to a substantial rise in cash reserves, which grew to $3.02 million from $337,655. Liminatus also reported a significant reduction in current liabilities, which fell to $3.04 million from $10.30 million, primarily due to the settlement of a $7.36 million liability related to a previous legal settlement.

Strategically, Liminatus completed a public offering on February 18, 2026, raising approximately $3.44 million in net proceeds. The offering included 8.27 million shares of common stock and warrants, which contributed to the company's cash position. Additionally, the company executed a warrant inducement agreement in June 2026, resulting in net proceeds of $1.62 million from the exercise of existing warrants. The company also finalized the acquisition of InnocsAI on July 2, 2026, which is expected to enhance its oncology-focused product portfolio.

Operationally, Liminatus has made strides in expanding its research capabilities, with research and development expenses reflecting its commitment to advancing its lead candidate, IBA101, a humanized anti-CD47 monoclonal antibody targeting solid tumors. The company’s employee headcount and customer engagement metrics were not disclosed in the filing, but the focus on R&D suggests a strategic emphasis on product development and market entry.

Looking ahead, Liminatus management expressed concerns regarding its ability to continue as a going concern, citing substantial doubt about its financial viability over the next year. The company plans to raise additional capital through equity and debt financing to support its operations. However, there is no assurance that it will be able to secure adequate funding under favorable terms, which could impact its future operations and strategic initiatives.